Henan Lingrui Pharmaceutical financials at a glance

+ Portfolio

The revenue of Henan Lingrui Pharmaceutical is reported as 3.31147 billion Yuan Renminbi in the fiscal year 2023. The earnings were 0 Yuan Renminbi per share in 2023, which was 178.26 higher than 2015. And about 0.79223 billion Yuan Renminbi are reported as free cash flow in the financials of Henan Lingrui Pharmaceutical 2023. Dividends of 0.8 Yuan Renminbi per share were paid to shareholders of Henan Lingrui Pharmaceutical stock SHSE:600285 in fiscal 2023.

Forecast

Financials

Year	Year	TTM	2021	2015	2013	2012	2011	2010	2009
Rev.	Revenue	N/A	¥2.69B	¥1.07B	¥686.97M	¥0.00M	¥448.78M	¥0.00M	¥0.00M
GM %	Gross Margin %	73.26%	73.72%	62.35%	57.19%	54.80%	52.40%	55.89%	60.70%
OM	Operating Margin	15.94%	13.98%	12.54%	8.92%	9.21%	3.95%	4.31%	5.32%
EPS	Earnings Per Share	¥0.93	¥0.64	¥0.23	¥0.10	¥0.07	¥0.03	¥0.02	¥0.07
Div.	Dividends	N/A	¥0.00	¥0.00	¥0.00	¥0.00	¥0.00	¥0.00	¥0.00
PR %	Payout Ratio %	0	0	0.00%	0	0	0	0	0
Sha.	Shares	N/AM	564.55M	535.48M	535.9M	451.62M	451.62M	451.62M	451.62M
OCF	Operating Cash Flow	N/A	¥845.69M	¥156.82M	¥127.27M	¥0.00M	¥40.49M	¥0.00M	¥0.00M
FCF	Free Cash Flow	N/A	¥768.78M	¥59.43M	¥-39.61M	¥0.00M	¥-23.41M	¥0.00M	¥0.00M
FCFS	Free Cash Flow Per Share	¥1.50	¥1.38	¥0.24	¥-0.08	¥-0.19	¥-0.05	¥-0.10	¥0.19

Henan Lingrui Pharmaceutical financials at a glance

Financials

Discover